Compare State Street SPDR S&P Biotech ETF (XBI) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs YieldMax Universe Fund of Option Income ETFs — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.38, while YieldMax Universe Fund of Option Income ETFs trades at $7.63. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| XBI | YMAX | |
|---|---|---|
Sector | Broad Market / Factor | Income / Options Overlay |
52-Week High | $164.28 | $13.26 |
52-Week Low | $86.92 | $7.27 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
YMAX trades at $7.63, down 1.04% today, with a bullish technical signal but bearish moving averages. The ETF maintains a consistent weekly dividend distribution schedule, though recent news highlights concerns about fee structures impacting payouts. Key resistance and support levels are clustered around $8, with the RSI indicating potential overbought conditions on a short-term basis.
The outlook is mixed; the fund's income strategy provides regular distributions, but high embedded costs and reliance on market volatility for returns present risks. Upside depends on favorable option-writing conditions, while downside is linked to market stability and expense drag.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
